FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML
December 19, 2017 - The FDA has approved bosutinib as a first-line treatment for patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), based on findings from the phase III BFORE trial. In the open-label study, the major molecular response (MMR) ...Leggi tutto